This is a working overview of carcinogenicity, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-12 and is reviewed periodically as new material appears.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Each Equip issue discussed the state of a particular games platform, looking back on significant releases with the benefit of hindsight and outlining future developments. For example, the GameCube issue featured lengthy retrospectives on The Legend of Zelda: The Wind Waker and Animal Crossing, plus a feature on upcoming titles that would use the GameCube – Game Boy Advance link cable. 'Specials issue ten: "Retro: The Collector's Series" This final edition in the Retro series reprinted all of the "Collector's Series" of articles from the main magazine. Each feature focused on a specific video game console of yesteryear and examined its history and the collectors market surrounding its rare or collectable games. Unusually for Edge, the majority of these articles were written by one video games journalist: Simon Parkin, a long-time freelance contributor to the magazine. "Edge presents FILE Volume 1 - Issues 1-12: The birth of a new generation" (2006) "Edge presents FILE Volume 2 - Issues 13-24: The new generation shows its strength" (2007) "Edge presents FILE Volume 3 - Issues 25-36: Videogame culture enters a new era" (2007)
Speckionian Genio (スペキオン星人ジェニオ, Supekion Seijin Jenio): A mirror-themed criminal from Planet Speckion who possesses the ability to travel through and trap people in reflective surfaces and is charged with trapping over 1,000,000 people on 124 planets in his mirror world as his personal "works of art" and murdering Tetsu's parents after they inadvertently surprised him during an attempt to escape S.P.D. on Earth. Two years prior to the series, he was captured by Tetsu and eventually incarcerated in Prison Satellite Alcapo (監獄衛星アルカポ, Kangoku Eisei Arukapo) in solitary confinement and denied access to reflective surfaces. Despite this, Genio would become famous among other Alienizers and inspire criminals to outdo or impress him. In the present, Tetsu questions Genio about a rash of copycat crimes, with the latter revealing the culprit is Bolapeno in exchange for whether Tetsu remembered what his mother said at the time of her death to make him cry. Using Tetsu's tear, Genio escapes and returns to Earth to make Tetsu suffer further. However, Tetsu discovers how to free Genio's victims before deleting him. During the events of the crossover film Tokusou Sentai Dekaranger vs. Abaranger, Saunaginnan resurrects Genio, but the latter is deleted by Deka Blue, Green, and Break and Abare Blue. Genio is voiced by Keiichi Noda (野田 圭一, Noda Keiichi). Karakazian Don Sanoa (カラカズ星人ドンサノーア, Karakazu Seijin Sanōa): A shark-themed mass-murderer from Planet Karakaz and the head of the Space Mafia Zundaz Family (宇宙マフィア・ズンダーズファミリー, Uchū Mafia Zundāzu Famirī).
=== Marketing === Liraglutide was approved by the US Food and Drug Administration (FDA) in 2014, and by the European Medicines Agency (EMA) in 2015, for adults with a body mass index (BMI) of 30 or greater (obesity) or a BMI of 27 or greater (overweight) who have at least one weight-related condition. Liraglutide was approved by the FDA in 2019, for treatment of children aged ten years of age or older with type 2 diabetes, making it the first non-insulin drug approved to treat type 2 diabetes in children since metformin was approved in 2000. Novo Nordisk made deals with generic manufacturers to enter the United States market in 2024. The FDA approved the first generic liraglutide in December 2024, and granted the approval to Hikma Pharmaceuticals USA
Sources: en.wikipedia.org
=== Apical Delta and Accessory Canals === Many teeth have a complex apical delta, consisting of many small accessory foramina branching from the main apical foramen. Each accessory canal is lined with connective tissue continuous with the pulp and periodontal ligament.
== Taxonomic distribution and evolutionary advantages == Action potentials are found throughout multicellular organisms, including plants, invertebrates such as insects, and vertebrates such as reptiles and mammals. Sponges seem to be the main phylum of multicellular eukaryotes that does not transmit action potentials, although some studies have suggested that these organisms have a form of electrical signaling, too. The resting potential, as well as the size and duration of the action potential, have not varied much with evolution, although the conduction velocity does vary dramatically with axonal diameter and myelination.
Rilwanu Lukman- former Minister of Petroleum Resources and Mines, Power, Steel; and former secretary general OPEC. Maikanti Baru - engineer, former GMD Of NNPC Limited. Mohammed Bello-Koko - former managing director of the Nigerian Ports Authority Muhammed Babandede - former Comptroller General (CG) of the Nigeria Immigration Service NIS. Ahmad Salihijo Ahmad - former managing director of Nigerian Rural Electrification Agency. M.T. Usman - former permanent secretary ministry of Works. Abubakar Dantsoho - Managing Director of the Nigerian Ports Authority (NPA). Hamman Bello - former Comptroller- General Of Nigeria Customs Service. Musa Yar'Adua - Minister of Lagos Affairs 1960 -1966, Matawalle of the Katsina Emirate. Muhammadu Ribadu – first minister of defence after independence, founder of the Nigerian Defence Academy. Mansur Muhtar – economist, former Nigerian Federal minister of finance (2008 -2010), former director World Bank, presently vice chairman, Islamic Development Bank. Tajudeen Abbas - Speaker of the House of Representatives of Nigeria. Abubakar Olusola Saraki – (Fulani/Yoruba); former president of the Senate. Gbemisola Ruqayyah Saraki – (Fulani/Yoruba); former Senator Kwara Central, current Minister of State. Transportation of the Federal Republic of Nigeria. Nigeria. Aisha Dikko - former attorney general, commissioner of Justice Kaduna. Bukola Saraki – (Fulani/Yoruba); former president of the Nigerian Senate; former Governor of Kwara State and former Senator Kwara Central, Nigeria. Captain Muhammad Bala Shagari – politician, former Nigerian Army officer.
=== Applications in Infectious diseases === One way to detect these pathogens is detect part of their genome by metagenomics sequencing (Next Generation Sequencing-mNGS), which can be targeted or untargeted.
Sources: en.wikipedia.org
Health facilities use storage called purpose-built units (also referred to pharmaceutical-grade units). These refrigerators or freezers are specifically designed for the storage of biologics, including vaccines. These units differ from standard household-grade units since it has microprocessor-based temperature control with a digital temperature sensor (thermistor, thermocouple, or resistance temperature detector), and fan-forced air circulation to promote uniform temperature around the unit. These storage are usually a stand-alone refrigerator or freezers because they perform better at keeping the temperature constant. A Household-grade refrigerator can also be an acceptable alternative to purpose-built units. However, the freezer compartment of this type is not recommended to store vaccines, and vaccines should be stored centrally inside the refrigerator. Many combination units cool the refrigerator using air from the freezer, resulting in different temperature zones inside the fridge. Placing vaccines near the cold air output from the freezer could cause too low temperature, and placing it at the very bottom could cause too high temperature. It is important not to place vaccines near the storage unit doors because it affects the temperature and exposes vaccines to light, reducing potency for some vaccines.
Quickly begin fermentation, out-competing other "wild yeasts" for nutrients in the must Completely utilize all fermentable sugars with a predictable sugar-to-alcohol conversion rate Have an alcohol-tolerance up to 15% or even higher depending on the winemaking style Have a high sulfur dioxide tolerance but low production of sulfur compounds such as hydrogen sulfide or dimethyl sulfide Produce a minimum amount of residual pyruvate, acetic acid and acetaldehyde Produce minimum foaming during fermentation which may create difficulties for cap management during maceration or cause bungs to pop out during barrel fermentation. Have high levels of flocculation and lees compaction that makes racking, fining and filtering of the wine easier. Inoculated (or pure cultured) yeasts are strains of Saccharomyces cerevisiae that have been identified and plated from wineries across the world (including notable producers from well-known wine regions such as Bordeaux, Burgundy, Napa Valley and the Barossa Valley).
The siliceous frustules of diatoms accumulate in fresh and brackish wetlands and lakes. Some peats and mucks contain a sufficient abundance of frustules such that they can be mined. Most of Florida's diatomaceous earths have been found in the muck of wetlands or lakes. The American Diatomite Corporation, from 1935 to 1946, refined a maximum of 145 tons per year from their processing plant near Clermont, Florida. Muck from several locations in Lake County, Florida was dried and burned (calcined) to produce the diatomaceous earth. It was formerly extracted from Lake Mývatn in Iceland. The commercial deposits of diatomite are restricted to Tertiary or Quaternary periods. Older deposits from as early as the Cretaceous Period are known, but are of low quality. Diatomite deposits rich in fossils have been located in New Zealand, but mining of the Foulden Maar deposits on an industrial scale, for conversion to animal feed, has drawn strong opposition.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.